Avéli logo

A new standard in cellulite treatment

Fast, real results that last1

New Beauty Award Winner 2024

Avéli named "Best Minimally Invasive Cellulite Treatment" by NewBeauty

New Beauty Award Winner 2024

Avéli named "Best Minimally Invasive Cellulite Treatment" by NewBeauty

Cellulite is problematic

  • Up to 90% of women have cellulite2
  • A significant majority are bothered by it3
  • Women are frustrated and disappointed because nothing has worked3
  • Over 70% willing to pay a minimum of $3K and ~50% willing to pay more than $4K up to $10K to treat it
aveli_model-min

Avéli provides long-term reduction in the appearance of cellulite in both the buttocks and thighs in a single procedure.5

It’s the only cellulite device that identifies and releases the culprit septa with real-time confirmation.1,5

Precise, predictable and repeatable results

Identify

Complex webs of septa tensioning the skin

Release

Controlled and precise release
of fibrous septa causing cellulite

Verify

Confirmation of release of culprit septa structures

Avéli is profitable.

  • Avéli offers dual practice opportunity as stand-alone
    treatment or add-on to overall treatment plan.*
  • No captial required.
  • Instantly accretive to the practice.

*Avéli has not been studied in combination with other treatments

Photo of a smiling doctor wearing a white lab coat with a stethescope around her neck.

Meaningful, visible results that last

B&A 1

Before

After

B&A 2

Before

After

B&A 3

Before

After

B&A 4

Before

After

B&A 5

Before

After

Experience the Avéli® difference.

Find out how this one-of-a-kind procedure can enhance your practice.

INTENDED USE AND SAFETY

Avéli® is indicated for long-term reduction in the appearance of cellulite in the buttocks and thigh areas of adult females as supported by clinical data demonstrating treatment benefits through one year of observation. Avéli is also indicated for soft tissue dissection during general and plastic surgical procedures. The most common side effects reported were mild pain within the first 24 hours and bruising and tenderness to the touch which typically resolved within 30 days. Some patients returned to normal activities within one day of the procedure and most within a week. As with any medical procedure, there are risks associated with the procedure. Refer to the Instructions for Use at myaveli.com/IFU for full safety information.

CONTRAINDICATIONS

Avéli should not be used on patients who have (or who are):

  1. Coagulant disorders/on anticoagulant medications
  2. Diabetic
  3. Had recent surgery (6 weeks)
  4. Pregnant
  5. Severe anemia
  6. Skin infections/open lesions
  7. Tumors
  8. Uncontrolled hypertension
  9. Varicose veins (in the area of treatment)
REFERENCES:
  1. Stevens WG, et al. Multicenter Pivotal Study Demonstrates Safety and Efficacy of a New Cellulite Procedure: Final Results at 12 Months [published online ahead of print, 2022 Nov 10]. Aesthet Surg J. 2022; sjac291
  2. Emanuele E. Cellulite: advances in treatment: facts and controversies. Clin Dermatol. 2013; 31(6):725-30.
  3. Data on file. Revelle Aesthetics, Inc. 2021. Patient Quantitative Research Report, June 2021.
  4. Revelle patient qualitative research, June 2021. N=500 women aged 25-60, concerned by their cellulite 38 What would you expect Procedure C to cost? Use the slider below to reflect your cost expectation.
  5. Avéli Precision Cellulite Device. Instructions for Use. Mountain View, CA: Revelle Aesthetics, Inc; 2024.